Daclizumab
- Generic Name
- Daclizumab
- Brand Names
- -
- Drug Type
- -
- Chemical Formula
- -
- CAS Number
- -
- Unique Ingredient Identifier
- -
- Associated Conditions
- -
- Associated Therapies
- -
Efficacy and Safety of Daclizumab in Participants With RRMS Switching From Natalizumab
Phase 3
Terminated
- Conditions
- Interventions
- First Posted Date
- 2016-08-29
- Last Posted Date
- 2019-09-27
- Lead Sponsor
- Biogen
- Target Recruit Count
- 41
- Registration Number
- NCT02881567
- Locations
- 🇵🇷
Research Site, Guaynabo, Puerto Rico
Study Comparing Efficacy and Safety of Mycophenolate Mofetil (Cellcept) With Delayed Introduction of Sirolimus and Discontinuation of Cyclosporine, With Those of Mycophenolate Mofetil and Long Term Continuation of Cyclosporine in Renal Transplant Recipients
Phase 3
Completed
- Conditions
- Interventions
- First Posted Date
- 2016-02-19
- Last Posted Date
- 2016-02-19
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 237
- Registration Number
- NCT02686619
A Study to Assess Immune Response in Pediatric Kidney Transplant Recipients Treated With Daclizumab (Zenapax)
Phase 4
Completed
- Conditions
- Interventions
- First Posted Date
- 2015-10-15
- Last Posted Date
- 2016-01-13
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 11
- Registration Number
- NCT02576145
A Study of Daclizumab (Zenapax) in Combination With Mycophenolate Mofetil (CellCept) and Sirolimus in Prevention of Acute Rejection in Heart Transplant Participants
Phase 4
Completed
- Conditions
- Interventions
- First Posted Date
- 2015-09-18
- Last Posted Date
- 2016-11-02
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 36
- Registration Number
- NCT02554955
Randomized Trial of 2 Antibody Induction Steroid Avoidance Protocols
Phase 4
Completed
- Conditions
- Interventions
- First Posted Date
- 2010-07-29
- Last Posted Date
- 2023-09-28
- Lead Sponsor
- University of Miami
- Target Recruit Count
- 200
- Registration Number
- NCT01172418
- Locations
- 🇺🇸
University of Miami Miller School of Medicine, Miami, Florida, United States
Safety and Efficacy Study of Thymoglobulin Versus IL2 Receptor Antagonists
Not Applicable
Completed
- Conditions
- Interventions
- First Posted Date
- 2009-03-10
- Last Posted Date
- 2016-04-26
- Lead Sponsor
- Medical University of South Carolina
- Target Recruit Count
- 200
- Registration Number
- NCT00859131
- Locations
- 🇺🇸
Medical University of South Carolina, Charleston, South Carolina, United States
Augmentation of Dendritic Cell-Based Vaccines in Melanoma Patients by Depletion of Regulatory T Cells in Stage IV Melanoma Patients
Phase 1
Completed
- Conditions
- First Posted Date
- 2009-02-19
- Last Posted Date
- 2009-02-19
- Lead Sponsor
- Radboud University Medical Center
- Target Recruit Count
- 15
- Registration Number
- NCT00847106
Safety and Effectiveness of Low Molecular Weight Sulfated Dextran in Islet Transplantation After Kidney Transplant
Thymoglobulin Versus Campath-1H Versus Daclizumab in Adult, Primary Deceased Donor Renal Transplantation
Phase 4
Completed
- Conditions
- Interventions
- First Posted Date
- 2008-05-28
- Last Posted Date
- 2023-10-18
- Lead Sponsor
- University of Miami
- Target Recruit Count
- 90
- Registration Number
- NCT00685061
- Locations
- 🇺🇸
University of Miami Division of Transplantation, Miami, Florida, United States
Daclizumab Versus Thymoglobulin in Renal Transplant Recipients With High Immunological Risk
Phase 3
Completed
- Conditions
- Interventions
- First Posted Date
- 2008-05-22
- Last Posted Date
- 2008-05-22
- Lead Sponsor
- University Hospital, Lille
- Target Recruit Count
- 227
- Registration Number
- NCT00682292
- Locations
- 🇫🇷
University Hospital of Lille, Lille, France
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2024. All Rights Reserved by MedPath